.8B, trading at NT$42.20 on the TWO. This SniperIQ fundamentals page covers Senhwa Biosciences's valuation, profitability (net margin -25497.5%), revenue (NT

What is Senhwa Biosciences's P/E ratio?

Senhwa Biosciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Senhwa Biosciences?

Senhwa Biosciences runs a net profit margin of -25497.5%, a gross margin of 48.0%, and an operating margin of -26630.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Senhwa Biosciences generate?

Senhwa Biosciences reported revenue of NT

Does Senhwa Biosciences pay a dividend?

Senhwa Biosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Senhwa Biosciences financially healthy?

Senhwa Biosciences carries a debt-to-equity ratio of 0.03x and a current ratio of 29.06x, with a market beta of 0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Senhwa Biosciences a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Senhwa Biosciences (6492) the key facts are: market cap NT

.8B, revenue NT

Track Senhwa Biosciences's full fundamentals live

Get Senhwa Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.